• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Choosing a prenatal diagnostic test: Microarray analysis shown equal to karyotyping

bys25qthea
January 1, 2013
in Obstetrics, Pediatrics
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Jan 1st – Chromosomal microarray analysis was successful in 98.8% of fetal samples.[tabs tab1=”2MM Rundown” tab2=”Full 2MM Report” tab3=”About the Authors”]

[tab]

Image: PD

1. Chromosomal microarray analysis was successful in 98.8% of fetal samples.

2. All of the aneuploidies and unbalanced arrangements identified via karyotyping were likewise identified by microarray, except for cases of balanced translocations and fetal triploidy.

3. Microarray allowed for identification of additional clinically relevant deletions and duplications in samples with a normal karyotype.

Microarray analyses have proven to be equally efficacious in identifying aneuploidies and unbalanced rearrangements and provided additional clinically relevant findings (e.g. segmental aneuplodies, copy number variants). However, there are certain limitations and issues that warrants attention. The microarray analyses did not identify balanced translocations and triploidies. Moreover, “uncertain” findings occurred in 3.4% (130 of 3822) karyotypically normal samples, more than 72.3% (94 of 130) of these cases could not be dismissed as benign and will likely require additional interpretation among a team of clinical geneticists, counselors, and laboratory directors, in addition to causing anxiety for the patient. Furthermore, while 1.7% or 1 in 60 samples with advanced maternal age or positive aneuploidy screening produced clinically relevant copy number variants, the small size and the subsequent mild phenotypic effects of these variants must also be considered before pushing for more invasive testing.

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

At this point in time, additional studies are necessary to confirm the frequencies of clinically relevant deletions and duplications, and patients must be carefully counseled on the risks of invasive testing versus the frequency and expected clinical severity of such microarray findings.

Click to read the study in NEJM

[/tab]

[tab]

Image: PD

1. Chromosomal microarray analysis was successful in 98.8% of fetal samples.

2. All of the aneuploidies and unbalanced arrangements identified via karyotyping were likewise identified by microarray, except for cases of balanced translocations and fetal triploidy.

3. Microarray allowed for identification of additional clinically relevant deletions and duplications in samples with a normal karyotype.

Primer: Fetal karyotyping is used as a confirmatory test after positive prenatal screening for various genetic anomalies, including Down’s Syndrome. Karyotyping detects major chromosomal deletions or translocations while chromosomal microarray analysis can detect smaller genomic deletions or duplications. Microarray analyses have identified a genetic cause in an additional 12-15% of children already diagnosed with altered neurocognitive development, in comparison to regular karyotyping. To further evaluate the reliability of microarray analyses in detecting chromosomal abnormalities, including those not seen on karyotyping, a prospective study comparing karyotyping and microarray analyses on prenatal diagnostic samples was performed in the present study.     

Background reading:

1. Cytogenetic and molecular genetic diagnostic tools

2. Overview of prenatal screening and diagnosis of Down syndrome

3. Sagoo GS, Butterworth AS, Sanderson S, et al. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med 2009;11:139-46.

 

This [prospective cohort study]: A total of 4,406 of women underwent chorionic-villus sampling and amniocentesis for microarray analysis and subsequent confirmatory karyotyping. Microarrays identified all of the autosomal and sex chromosome aneuploidies (7.4 and 1.3% respectively) and unbalanced rearrangements seen via karyotyping. Among 3,822 fetal samples with normal karyotypes, 96 (2.5%) had deletions or duplications of clinical significance. Clinically relevant findings via microarray were reported in 6% of cases with suspected structural anomalies, 1.7% of with advanced maternal age, and 1.6% testing positive for Down’s, all of which had normal karyotypes.

In sum: Microarray analyses have proven to be equally efficacious in identifying aneuploidies and unbalanced rearrangements and provided additional clinically relevant findings (e.g. segmental aneuplodies, copy number variants). However, there are certain limitations and issues that warrants attention. The microarray analyses did not identify balanced translocations and triploidies. Moreover, “uncertain” findings occurred in 3.4% (130 of 3822) karyotypically normal samples, more than 72.3% (94 of 130) of these cases could not be dismissed as benign and will likely require additional interpretation among a team of clinical geneticists, counselors, and laboratory directors, in addition to causing anxiety for the patient. Furthermore, while 1.7% or 1 in 60 samples with advanced maternal age or positive aneuploidy screening produced clinically relevant copy number variants, the small size and the subsequent mild phenotypic effects of these variants must also be considered before pushing for more invasive testing. At this point in time, additional studies are necessary to confirm the frequencies of clinically relevant deletions and duplications, and patients must be carefully counseled on the risks of invasive testing versus the frequency and expected clinical severity of such microarray findings.

Click to read the study in NEJM

Written by [EP] and [RR]

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

[/tab]

[tab]

Elizabeth Park: Elizabeth is a 4th year M.D. Candidate at Boston University School of Medicine.

 

 

 

 

Rif Rahman: Rif is a 4th year M.D. candidate at Harvard Medical School, currently completing a research year investigating the use of conventional and advanced imaging techniques to assess treatment response of high grade gliomas.

 

 

 

[/tab]

[/tabs]

 

Previous Post

The NICE-SUGAR trial: Intensive glycemic control harmful in the ICU [Classics Series]

Next Post

Long-term physical activity is associated with several health markers in the serum metabolome

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series
Pediatrics

Homicide deaths are on the rise for children living in the United States

January 30, 2023
Next Post

Long-term physical activity is associated with several health markers in the serum metabolome

Classics Series, Landmark Trials in Medicine

The ADVANCE trial: Intensive glycemic control reduces risk of nephropathy [Classics Series]

[Physician Comment] Suture closure superior to staples after cesarean delivery

[Physician Comment] Suture closure superior to staples after cesarean delivery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options